BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 10340400)

  • 1. Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines.
    Lu M; Levin J; Sulpice E; Sequeira-Le Grand A; Alemany M; Caen JP; Han ZC
    Exp Hematol; 1999 May; 27(5):845-52. PubMed ID: 10340400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of arsenic trioxide (As2O3) on human megakaryocytic leukemia cell lines. With a comparison of its effects on other cell lineages.
    Alemany M; Levin J
    Leuk Lymphoma; 2000 Jun; 38(1-2):153-63. PubMed ID: 10811458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.
    Zhang W; Ohnishi K; Shigeno K; Fujisawa S; Naito K; Nakamura S; Takeshita K; Takeshita A; Ohno R
    Leukemia; 1998 Sep; 12(9):1383-91. PubMed ID: 9737686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.
    Wang ZG; Rivi R; Delva L; König A; Scheinberg DA; Gambacorti-Passerini C; Gabrilove JL; Warrell RP; Pandolfi PP
    Blood; 1998 Sep; 92(5):1497-504. PubMed ID: 9716575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia.
    Cai X; Shen YL; Zhu Q; Jia PM; Yu Y; Zhou L; Huang Y; Zhang JW; Xiong SM; Chen SJ; Wang ZY; Chen Z; Chen GQ
    Leukemia; 2000 Feb; 14(2):262-70. PubMed ID: 10673743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations.
    Zhu XH; Shen YL; Jing YK; Cai X; Jia PM; Huang Y; Tang W; Shi GY; Sun YP; Dai J; Wang ZY; Chen SJ; Zhang TD; Waxman S; Chen Z; Chen GQ
    J Natl Cancer Inst; 1999 May; 91(9):772-8. PubMed ID: 10328107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice.
    Kinjo K; Kizaki M; Muto A; Fukuchi Y; Umezawa A; Yamato K; Nishihara T; Hata J; Ito M; Ueyama Y; Ikeda Y
    Leukemia; 2000 Mar; 14(3):431-8. PubMed ID: 10720138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic trioxide induces apoptosis in leukemia/lymphoma cell lines via the CD95/CD95L system.
    Zhu J; Okumura H; Ohtake S; Nakamura S; Nakao S
    Oncol Rep; 2003; 10(3):705-9. PubMed ID: 12684647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation.
    Rojewski MT; Baldus C; Knauf W; Thiel E; Schrezenmeier H
    Br J Haematol; 2002 Mar; 116(3):555-63. PubMed ID: 11849211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenylarsine oxide (PAO) more intensely induces apoptosis in acute promyelocytic leukemia and As2O3-resistant APL cell lines than As2O3 by activating the mitochondrial pathway.
    Sahara N; Takeshita A; Kobayashi M; Shigeno K; Nakamura S; Shinjo K; Naito K; Maekawa M; Horii T; Ohnishi K; Kitamura K; Naoe T; Hayash H; Ohno R
    Leuk Lymphoma; 2004 May; 45(5):987-95. PubMed ID: 15291359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins.
    Chen GQ; Zhu J; Shi XG; Ni JH; Zhong HJ; Si GY; Jin XL; Tang W; Li XS; Xong SM; Shen ZX; Sun GL; Ma J; Zhang P; Zhang TD; Gazin C; Naoe T; Chen SJ; Wang ZY; Chen Z
    Blood; 1996 Aug; 88(3):1052-61. PubMed ID: 8704214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects.
    Baj G; Arnulfo A; Deaglio S; Mallone R; Vigone A; De Cesaris MG; Surico N; Malavasi F; Ferrero E
    Breast Cancer Res Treat; 2002 May; 73(1):61-73. PubMed ID: 12083632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
    Shao W; Fanelli M; Ferrara FF; Riccioni R; Rosenauer A; Davison K; Lamph WW; Waxman S; Pelicci PG; Lo Coco F; Avvisati G; Testa U; Peschle C; Gambacorti-Passerini C; Nervi C; Miller WH
    J Natl Cancer Inst; 1998 Jan; 90(2):124-33. PubMed ID: 9450572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNAs contribute to promyelocyte apoptosis in As2O3-treated APL cells.
    Liang H; Li X; Wang L; Yu S; Xu Z; Gu Y; Pan Z; Li T; Hu M; Cui H; Liu X; Zhang Y; Xu C; Guo R; Lu Y; Yang B; Shan H
    Cell Physiol Biochem; 2013; 32(6):1818-29. PubMed ID: 24356076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance.
    Lehmann S; Bengtzen S; Paul A; Christensson B; Paul C
    Eur J Haematol; 2001 Jun; 66(6):357-64. PubMed ID: 11488934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.
    Chen GQ; Shi XG; Tang W; Xiong SM; Zhu J; Cai X; Han ZG; Ni JH; Shi GY; Jia PM; Liu MM; He KL; Niu C; Ma J; Zhang P; Zhang TD; Paul P; Naoe T; Kitamura K; Miller W; Waxman S; Wang ZY; de The H; Chen SJ; Chen Z
    Blood; 1997 May; 89(9):3345-53. PubMed ID: 9129041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preliminary study on the arsenic trioxide-induced NB4 cell apoptosis and its molecular mechanisms].
    Chen G; Zhu J; Shi X; Zhong H; Liu W; Jin X; Tang W; Li X; Ni J; Xiong S; Shen Z; Ma J; Zhang P; Zhang T; Claude G; Chen S; Chen L; Wang Z
    Zhonghua Xue Ye Xue Za Zhi; 1997 Jan; 18(1):25-8. PubMed ID: 15622746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of intracellular arsenic trioxide for therapeutic response in acute promyelocytic leukemia.
    Sahu GR; Jena RK
    Am J Hematol; 2005 Feb; 78(2):113-6. PubMed ID: 15682419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis.
    Kitamura K; Minami Y; Yamamoto K; Akao Y; Kiyoi H; Saito H; Naoe T
    Leukemia; 2000 Oct; 14(10):1743-50. PubMed ID: 11021749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells.
    Li X; Ding X; Adrian TE
    Cancer Invest; 2004; 22(3):389-400. PubMed ID: 15493360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.